The Sorin Group: Europe's Last, Best Hope in Cardiovascular Devices
The contribution that Europeans, particularly European physicians and surgeons, have made to the cardiology and cardiovascular industries has been enormous. Why then have Europeans lagged far behind their US counterparts in one important area--company creation? If there is a candidate to play in the cardiovascular device industry's elite ranks, it's Sorin Group, a company with a diverse holding in a wide range of cardiology and cardiovascular device segments.
By David Cassak
From virtually any point of view—clinical, technological, scientific--today's cardiovascular device industry would be unimaginable without the contribution of dozens of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.